A Phase I, Open-Label, Randomized, Four-Treatment Period, Four-Sequence, Single-Dose, Crossover, Pharmacokinetic Bioequivalence Study Comparing Pirfenidone Tablet and Capsule Dosage Forms in Healthy Adult Volunteers

Trial Profile

A Phase I, Open-Label, Randomized, Four-Treatment Period, Four-Sequence, Single-Dose, Crossover, Pharmacokinetic Bioequivalence Study Comparing Pirfenidone Tablet and Capsule Dosage Forms in Healthy Adult Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs Pirfenidone (Primary) ; Pirfenidone (Primary)
  • Indications Acute lung injury; Idiopathic pulmonary fibrosis
  • Focus Pharmacokinetics
  • Sponsors Roche
  • Most Recent Events

    • 14 Aug 2017 Primary endpoint (AUC from Time Zero to Infinity (AUC[0-inf]) of Pirfenidone, in fed and fasted state, 1 801-mg tablet vs 3 267-mg capsules) has been met as per the results published in the Advances in Therapy
    • 14 Aug 2017 Primary endpoint (Area Under the Plasma Concentration Versus Time Curve (AUC) from Time Zero to the Time of the Last Quantifiable Concentration (AUC[0-t]) of Pirfenidone, in fed and fasted state, 1 801-mg tablet vs 3 267-mg capsules) has been met as per the results published in the Advances in Therapy
    • 14 Aug 2017 Primary endpoint (Peak Plasma Concentration (Cmax) of Pirfenidone, in fed state, 1 801-mg tablet vs 3 267-mg capsules) has not been met as per the results published in the Advances in Therapy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top